Skip to main content
In stock|Immunotherapy (Investigational)

Rilotumumab

Oncology TypeSolid Tumour
Drug Class / MechanismCostimulatory / Bispecific Agent
No Image
Description

Rilotumumab is classified as a Costimulatory / Bispecific Agent, sourced for use within our Immunotherapy (Investigational) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryImmunotherapy (Investigational)
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3